Protocol Ledger

NCT06275919 · Phase II · RECRUITING

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Interventional Phase II clinical trial protocol NCT06275919 sponsored by Istituto Oncologico Veneto IRCCS in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-23 Enrollment: 104 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06275919
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)104 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06275919
Protocol FieldVerified Registry Value
NCT IdentifierNCT06275919
Consolidated Lead SponsorIstituto Oncologico Veneto IRCCS
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment104 participants (ESTIMATED)
Registered Start Date2024-09-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06275919
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->
IRCCS Ospedale San RaffaeleMilan, ItalyOpen Hospital Dossier ->
Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI